Raymond James Financial Services Advisors’s AIM ImmunoTech AIM Stock Holding History

Raymond James Financial Services Advisors’s Portfolio AIM Stock Details AIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-370	Closed	-$11.5K	–	3462
2022 Q4	$11.5K	Hold	370	–	–	﹤0.01%	3189
2022 Q3	$22K	Sell	370 -5	-1%	-$350	﹤0.01%	3156
2022 Q2	$29K	Buy	+375	New	+$36K	﹤0.01%	3135
2022 Q1	–	Sell	-485	Closed	-$45K	–	3536
2021 Q4	$45K	Hold	485	–	–	﹤0.01%	3199
2021 Q3	$98K	Buy	485 +5	+1%	+$1.01K	﹤0.01%	3121
2021 Q2	$103K	Buy	+480	New	+$103K	﹤0.01%	3135

Other funds holding AIM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Raymond James Financial Services Advisors's AIM Position: Q1 2023 in Review

Raymond James Financial Services Advisors sold out of AIM ImmunoTech (AIM) in Q1 2023, closing a stake of 370 shares — an estimated $11.5K sold.

Raymond James Financial Services Advisors first reported a position in AIM in Q2 2021 and held it in 6 quarters. The position peaked at $103K in Q2 2021. 31 funds tracked by Wall St. Rank hold AIM as of Q1 2023.

Raymond James Financial Services Advisors reported no remaining AIM ImmunoTech position as of Q1 2023 after selling out during the quarter.
Raymond James Financial Services Advisors sold 370 AIM ImmunoTech shares in Q1 2023, an estimated $11.5K.
Raymond James Financial Services Advisors first reported a position in AIM ImmunoTech in Q2 2021 and held it in 6 quarters.
Raymond James Financial Services Advisors's AIM ImmunoTech position peaked at $103K in Q2 2021.
31 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q1 2023.

Based on Raymond James Financial Services Advisors's 13F filing for Q1 2023, filed 14 Apr 2023.